Beta Cat Pharmaceuticals
Houston, US · Founded 2014 · Delaware corporation
Founders & leadership
SS
Sunil SharmaCo-Chief Medical Officer
JP
Jonathan P. NorthrupinPresident/Secretary/Chief Executive Officer
AC
Alain CappelutiChief Financial Officer
SH
CC
Casey CunninghamCo-Chief Medical Officer
Board
KC
Kenneth CarterBoard director
JC
Joseph CunninghamBoard director
Reported raises · per SEC filings
Form D private placements$5.5M disclosed across 4 rounds · 2014–2018
▶$2.6MraisedJun 2018 · 3 investors · PharmaceuticalsRule 506(b)
▶$2.6MraisedJun 2018 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jonathan NorthrupDirector
- James EadieDirector
- Rahul ArasExecutive Officer
- Kenneth CarterDirector
- Joe CunninghamDirector
- Uma BhattExecutive Officer
- Offering amount
- $6M
- Amount sold
- $2.6M
- First sale
- Jun 2018
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$1.4MraisedDec 2017 · 17 investors · PharmaceuticalsRule 506(b)
▶$1.4MraisedDec 2017 · 17 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Kenneth CarterDirector
- Jonathan NorthrupExecutive Officer, Director
- Scott JordanExecutive Officer, Director
- Joseph CunninghamDirector
- Sunil SharmaExecutive Officer, Director
- Offering amount
- $1.4M
- Amount sold
- $1.4M
- Minimum investment
- $25K
- Proceeds to insiders
- $125K
- First sale
- Jul 2016
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$1MraisedJul 2015 · 2 investors · BiotechnologyRule 506(b)
▶$1MraisedJul 2015 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sunil SharmaExecutive Officer, Director
- Kenneth CarterDirector
- Joseph CunninghamDirector
- Jonathan P. NorthrupExecutive Officer, Director
- Alain CappelutiExecutive Officer
- Stephen HorriganExecutive Officer
- Casey CunninghamExecutive Officer
- Offering amount
- $3M
- Amount sold
- $1M
- First sale
- Jun 2015
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$500KraisedJul 2014 · 1 investors · BiotechnologyRule 506(b)
▶$500KraisedJul 2014 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Alain CappelutiExecutive Officer
- Sunil SharmaExecutive Officer, Director
- Jonathan P NorthrupExecutive Officer, Director
- Kenneth C CarterDirector
- Offering amount
- $500K
- Amount sold
- $500K
- Minimum investment
- $500K
- First sale
- Jun 2014
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2018 | $300K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- How much funding has Beta Cat Pharmaceuticals raised?
- Beta Cat Pharmaceuticals has disclosed $5.5M raised across 4 rounds.
- Where is Beta Cat Pharmaceuticals headquartered?
- Beta Cat Pharmaceuticals is headquartered in Houston, US.